Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02768727 · ClinicalTrials.gov registry record · Phase 2

A Test of Neural Inertia in Humans With Xenon

A Phase 2 study, sponsored by University of Pennsylvania.

Completed
Registry status
Phase 2
Development phase
21
Enrollment target

NCT02768727: Completed Phase 2 study, sponsored by University of Pennsylvania.

NCT02768727 is a Phase 2 study that has completed, run by University of Pennsylvania. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02768727, a Phase 2 study, has completed, sponsored by University of Pennsylvania.

COMPLETED
Registry status
Phase 2
Development phase
21 participants
Enrollment target

Study Summary

The dual objectives of this study are to determine if the phenomenon of neural inertia is present in humans and to determine whether the order of neurocognitive function is invariant among anesthetic agents. This study will enroll 24 healthy volunteers, ages 20-40 years, who will receive xenon gas (concentrations ranging from 0% to 60%) delivered via inhaled route through the ENHANCER 3000.

Interventions

  • DRUG Xenon

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2016-04
Est. Completion 2021-12-01
Phase Phase 2

Sponsor

University of Pennsylvania

1,423 total trials

What the Registry Record Tells You About NCT02768727

The ClinicalTrials.gov registry entry for NCT02768727 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Xenon is the first listed.

NCT02768727 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02768727 about?

NCT02768727 is a clinical study titled "A Test of Neural Inertia in Humans With Xenon". The dual objectives of this study are to determine if the phenomenon of neural inertia is present in humans and to determine whether the order of neurocognitive function is invariant among anesthetic agents. This study will enroll 24 healthy volunteers, ages 20-40 years, who will receive xenon gas (...

What is the current status of trial NCT02768727?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2016-04. Estimated completion is 2021-12-01.

What interventions are being tested in trial NCT02768727?

The interventions under investigation include: Xenon (DRUG).

Who is sponsoring clinical trial NCT02768727?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.